News

Allergan has received FDA approval for OZURDEX (dexamethasone intravitreal implant) 0.7mg, as the first drug therapy for the treatment of macular edema, following branch retinal vein occlusion (BRVO)

Cytokinetics has initiated first-time-in-humans, phase-I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a fast skeletal muscle troponin activator, and is the lead drug candidate of

Highlights: Group operating profit before non-recurring costs GBP334,000 (2008: GBP1,033,000) Non-recurring costs of GBP1,117,000 primarily represent business relocation expenses and redundancy and employment contract severance costs Loss before

Canada-based Paladin Labs and Sylphar have entered into an agreement to develop and market an oral dissolving teeth whitening film strip in Europe. Under the agreement, Sylphar and

Seattle Genetics has initiated phase-II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that

Antares Pharma’ partner BioSante has said that the LibiGel Safety Study External Executive Committee has recommended continuation of the LibiGel phase-III clinical program. The decision of the committee

Novartis has received FDA approval for Ilaris (canakinumab), for the treatment of cryopyrin-associated periodic syndrome (CAPS) in children and adults. The FDA granted priority review to Ilaris, based

Pfizer has announced that the US Securities and Exchange Commission (SEC) has declared effective Pfizer’ Registration Statement on Form S-4. The Form S-4 registers with the SEC Pfizer’s

Amsterdam Molecular Therapeutics’ (AMT) lead product ,Glybera, has demonstrated long-term health benefits in one-time administration. The data from two clinical trials showed that one administration with Glybera brings